News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Myeloma Paper of the Day, June 4th, suggested by Robert Orlowski
Jun 4, 2024, 14:44

Myeloma Paper of the Day, June 4th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Phase III BENEFIT trial shows addition of bortezomib to isatuximab/lenalidomide/dexamethasone for transplant-ineligible myeloma patients improves CR rate (33% vs. 58%) and MRD-negativity (26% vs. 53%)(the primary endpoint).”

Source: Robert Orlowski/X

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Authors: Xavier Leleu, et al.

Myeloma Paper of the Day, June 4th, suggested by Robert Orlowski

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.

Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Agathe Waultier-Rascalou Alberto Santagostino Amine Kasmi Arthur Bobin Aurore Perrot BENEFIT trial Benoit Bareau Bertrand Arnulf Bertrand Joly Borhane Slama Bortezomib Brieuc Cherel Bruno Royer cancer Celine Kennel Christophe Roul Claire Calmettes Claire Dingremont Clara Mariette Cyrille Hulin Cyrille Touzeau Daniela Robu-Cretu dexamethasone Emilie Chalayer Emmanuelle Bourgeois Florence Lachenal François Vergez Frederique Orsini-Piocelle Helene Demarquette Helene Gardeney Hervé Avet-Loiseau Isatuximab Jacques Delaunay Jean-Sebastien Bladé Jerome Lambert Jill Corre Julie Gay Kamel Laribi Karim Belhadj Laure Vincent Laurent Frenzel Laurent Garderet Lenalidomide Lionel Karlin Lydia Montes Mamoun Dib Margaret Macro Marie-Lorraine Chretien MD Anderson Cancer Center Mohamad Mohty Mourad Tiab multiple myeloma Muriel Newinger-Porte Murielle Roussel Myeloma Paper of the Day Noemie Bigot Olivier Decaux OncoDaily Oncology Philippe Moreau Pierre Lebreton Rakiba Belkhir Reza Tabrizi Robert Orlowski Ronan Le Calloch Salomon Manier Selim Corm Sophie Rigaudeau Thierry Facon Thomas Chalopin Thorsten Braun Valentine Richez-Olivier Xavier Leleu
Special Coverage
Blog
Dec 30, 2024, 19:52
CelloType: A New Machine Learning Tool for Analyzing Cancer Cells and Tissues
Blog
Dec 30, 2024, 19:26
“QI Scholar Nursing Presentations Part 2” from the SIOP Nursing Network
Science
Dec 30, 2024, 13:52
Nico Gagelmann: Selected clinical studies 2024 in hematology
Insight
Dec 30, 2024, 13:43
Roupen Odabashian: When it comes to real-life cases, physicians still outperform AI
Blog
Dec 30, 2024, 13:42
Shaban Juma: The key to being one step ahead in the fight against cancer
Positive
Dec 30, 2024, 13:42
Improving the lives of children with cancer everywhere - St. Jude Children's Research Hospital
Blog
Dec 30, 2024, 13:37
Matthew Pech: The failure of ex vivo gene therapy for sickle cell and the role of the TPP in the drug development process
Insight
Dec 30, 2024, 13:35
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
Insight
Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Blog
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Insight
Dec 30, 2024, 13:23
Satya Prakash Yadav: 2024 blockbuster Menin inhibitor for infant ALL
Insight
Dec 30, 2024, 13:10
Promising response to lurbinectedin in NUT carcinoma by M.V. Sánchez Becerra et al. - Vivek Subbiah